Subjective well-being, craving for cannabis and compliance or medication switch in a randomized doubleblind study with olanzapine and risperidone.

Completed

• Registration Number: NL-OMON22184

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

1. Patients should be able to understand the study description and give informed consent;

2. Diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder according to DSM IV;

Exclusion Criteria

1. Pregnancy;

2. Lactating women;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Subjective Well-being under Neuroleptics scale (SWN);<br /><br>2. Obsessive Compulsive Drug Use Scale (OCDUS);<br /><br>3. Positive And Negative Symptoms Scale (PANSS) based on information from the semi-structured interview (SCI- PANSS);<br /><br>4. Calgary Depression Rating Scale (CDRS);<br /><br>5. ESRS: Extra pyramidal Symptom Rating Scale;<br /><br>6. Clinical Global Impression (CGI);<br /><br>7. Y-BOCS (Yale Brown Obsessive Compulsive Scale);<br /><br>8. Desires for Drugs Questionnaire (DDQ);<br /><br>9. Drug Use Self Report (DUSR);<br /><br>10. Recent Drug Use Urinalysis (RDUU).

Secondary Outcome Measures

Name	Time	Method
1. Drop out from the study;<br /><br>2. Medication compliance and medication switch, symptoms and rehospitalisations during one year follow up, measured with the Life Chart Schedule (LCS).